Legend Biotech (NASDAQ:LEGN) Rating Lowered to “In-Line” at Evercore

Legend Biotech (NASDAQ:LEGN – Get Free Report) was downgraded by stock analysts at Evercore from an “outperform” rating to an “in-line” rating in a report issued on Friday, MarketBeat reports.

A number of other equities analysts have also commented on LEGN. JPMorgan Chase & Co. cut their price objective on Legend Biotech from $35.00 to $33.00 and set a “neutral” rating on the stock in a research note on Friday, October 9th. Benchmark reiterated a “buy” rating on shares of Legend Biotech in a report on Tuesday, July 28th. Oppenheimer decreased their target price on shares of Legend Biotech from $40.00 to $25.00 and set a “market perform” rating for the company in a research report on Wednesday. UBS Group restated a “buy” rating and set a $65.00 price target on shares of Legend Biotech in a report on Monday, September 28th. Finally, TD Cowen dropped their price target on shares of Legend Biotech from $29.00 to $24.00 and set a “hold” rating on the stock in a research report on Wednesday, August 12th. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Legend Biotech presently has a consensus rating of “Moderate Buy” and an average price target of $50.85.

View Our Latest Stock Analysis on Legend Biotech

Legend Biotech Stock Down 5.6%

LEGN traded down $1.04 during midday trading on Friday, hitting $17.50. 3,029,718 shares of the company were exchanged, compared to its average volume of 2,468,718. The firm has a market capitalization of $3.39 billion, a P/E ratio of -1,748.25 and a beta of 0.55. Legend Biotech has a 1-year low of $16.24 and a 1-year high of $37.50. The firm’s 50 day moving average price is $19.57 and its 200-day moving average price is $22.12.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The firm had revenue of $359.50 million for the quarter, compared to analyst estimates of $361.46 million. Legend Biotech had a negative return on equity of 0.03% and a negative net margin of 0.02%. The business’s revenue was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.05) EPS. On average, sell-side analysts predict that Legend Biotech will post -0.02 earnings per share for the current fiscal year.

Insider Activity at Legend Biotech

In other news, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the firm’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $9.46, for a total transaction of $258,920.20. Following the completion of the sale, the director owned 52,731 shares of the company’s stock, valued at $498,835.26. This trade represents a 34.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Carlos Santos sold 5,430 shares of Legend Biotech stock in a transaction on Monday, September 21st. The shares were sold at an average price of $9.14, for a total transaction of $49,630.20. Following the completion of the sale, the chief financial officer owned 14,246 shares of the company’s stock, valued at $130,208.44. This represents a 27.60% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.02% of the company’s stock.

Institutional Investors Weigh In On Legend Biotech

Large investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. acquired a new stake in Legend Biotech in the second quarter worth $55,307,000. Squarepoint Ops LLC boosted its position in shares of Legend Biotech by 60.4% during the 2nd quarter. Squarepoint Ops LLC now owns 769,252 shares of the company’s stock worth $22,216,000 after purchasing an additional 289,772 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Legend Biotech by 29.5% during the 1st quarter. Renaissance Technologies LLC now owns 521,800 shares of the company’s stock worth $9,439,000 after purchasing an additional 119,000 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Legend Biotech by 343.6% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 406,901 shares of the company’s stock worth $7,361,000 after purchasing an additional 315,176 shares in the last quarter. Finally, Tidal Investments LLC grew its stake in shares of Legend Biotech by 34.0% in the 2nd quarter. Tidal Investments LLC now owns 240,476 shares of the company’s stock valued at $6,945,000 after buying an additional 61,023 shares during the period. 70.89% of the stock is currently owned by institutional investors and hedge funds.

Legend Biotech Company Profile

(Get Free Report)

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.

See Also

Analyst Recommendations for Legend Biotech (NASDAQ:LEGN)

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.